Huabei Pharmaceutical announced that Huabei Pharmaceutical Huasheng Co., Ltd., a holding subsidiary of the company, recently received Polymyxin Sulfate B “Notice of Approval for the Marketing Application of Chemical Ingredients” approved and issued by the State Drug Administration. This drug is used to treat acute infections caused by Pseudomonas aeruginosa sensitive strains, and is the drug of choice for urinary tract, meningeal, and bloodstream infections caused by this type of bacteria. Up to now, the total investment in research and development of this drug is 10.99 million yuan. This approval will enrich the company's product line, but it will not have a significant impact on current operating results. The drug will be produced and marketed after passing the GMP compliance check.

Zhitongcaijing · 06/10 09:49
Huabei Pharmaceutical announced that Huabei Pharmaceutical Huasheng Co., Ltd., a holding subsidiary of the company, recently received Polymyxin Sulfate B “Notice of Approval for the Marketing Application of Chemical Ingredients” approved and issued by the State Drug Administration. This drug is used to treat acute infections caused by Pseudomonas aeruginosa sensitive strains, and is the drug of choice for urinary tract, meningeal, and bloodstream infections caused by this type of bacteria. Up to now, the total investment in research and development of this drug is 10.99 million yuan. This approval will enrich the company's product line, but it will not have a significant impact on current operating results. The drug will be produced and marketed after passing the GMP compliance check.